

ExonHit enters into a liquidity agreement

Paris, France – May 19, 2009 – ExonHit Therapeutics (ISIN: FR0004054427) has engaged Natixis Securities to implement a liquidity agreement, effective May 19, 2009, for a period of one year with tacit renewal.

This contract complies with the Business Ethic Charter of the French Financial Market Association of September 23, 2008 which was approved by the French stock market authority on October 1, 2008.

The implementation of such liquidity agreement was decided by the Company's Management Board on May 13, 2009 pursuant to a shareholders' authorization granted at the Ordinary General Meeting held on April 24, 2009.

ExonHit has set aside Euro 400,000 in support of the implementation of this agreement. For information, based on the price of the ExonHit Therapeutics share at the close of the market on May 15, 2009, i.e. Euro 3.20 per share, this amount would purchase a maximum of 125,000 shares.

The maximum repurchase price is Euro 7 per share.

As of this date, the Company does not hold treasury shares.

About ExonHit Therapeutics

ExonHit Therapeutics (Alternext: ALEHT) is a fast emerging healthcare player active in both therapeutics and diagnostics. The Company is applying its proprietary technology, based on the analysis of alternative RNA splicing, to develop innovative blood based diagnostic tests and therapeutics for neurodegenerative and cancer indications. ExonHit has a balanced investment strategy with internal development programs and strategic collaborations, in particular with bioMérieux and Allergan.

ExonHit is headquartered in Paris, France and has U.S. offices in Gaithersburg, Maryland. The Company is listed on Alternext of NYSE Euronext Paris. For more information, please visit <http://www.exonhit.com>.

Disclaimer

This press release contains elements that are not historical facts including, without limitation, certain statements on future expectations and other forward-looking statements. Such statements are based on management's current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those anticipated.

In addition, ExonHit Therapeutics, its shareholders, and its affiliates, directors, officers, advisors and employees have not verified the accuracy of, and make no representations or warranties in relation to, statistical data or predictions contained in this press release that were taken or derived from third party sources or industry publications, and such statistical data and predictions are used in this press release for information purposes only.

Finally, this press release may be drafted in the French and English languages. In an event of differences between the texts, the French language version shall prevail.

ExonHit Therapeutics

Media Contact

Corinne Hoff

+33 1 58 05 47 04

corinne.hoff@exonhit.com

Investor Contact

Philippe Rousseau, CFO

+1 240 404 0191

philippe.rousseau@exonhit.com